The effect of somatostatin on platelets: in vivo and in vitro studies.
The influence of somatostatin on platelets was studied in healthy volunteers. After a bolus injection of 250 microgram somatostatin followed by a three hour infusion at a rate of 250 microgram somatostatin/hr a statistically significant fall of platelet count and impairment of platelet aggregation was observed. The aggregation inhibiting effect of somatostatin at the end of the three hour infusion is clinically unimportant as compared to the effect of aspirin. In vitro concentrations up to 10.0 microgram somatostatin per ml do not show any effect on platelet aggregation and platelet stickiness. Endocrinologically active doses of somatostatin in short term infusions are very unlikely to cause bleeding disorders.
D000293:Adolescent; D000328:Adult; D001241:Aspirin / Q000009:adverse effects; D001772:Blood Cell Count; D001778:Blood Coagulation Disorders / Q000139:chemically induced; D001792:Blood Platelets / Q000502:physiology*; D006801:Humans; D010973:Platelet Adhesiveness; D010974:Platelet Aggregation; D013004:Somatostatin / Q000009:adverse effects
D013004:Somatostatin; D001241:Aspirin